3月17日 - ** 糖尿病技术公司 Tandem Diabetes Care TNDM.O股价盘前上涨 ~4.29% 至 22.85 美元
** Piper Sandler将TNDM的评级从 "中性 "上调至 "增持"，理由是药房定价优势得到改善，国际直接市场机会不断增加。
** 券商称，未来三年的收入预期将有显著的上升空间，这将推动股价上涨
** 预计该公司新的无内胎 Mobi 产品将在未来几年提高泵的出货量，并帮助 TNDM 重新夺回市场份额。
** Piper Sandler将该公司的目标价上调至 33 美元，较上一交易日收盘价上涨 50.6%
** 24家券商中有11家将该股评级为 "买入 "或更高，13家为 "持有"；其PT中值为27.50美元--LSEG数据
** 截至上次收盘，该股今年累计下跌 ~0.3%
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.